Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

September 16, 2019 Issue

09736-cover-openercxd.jpg

September 16, 2019 Cover

Volume 97, Issue 36

On Sept. 17, 1999, Jesse Gelsinger died after receiving an experimental gene therapy from James Wilson’s lab at the University of Pennsylvania. That tragedy waylaid Wilson’s career and almost shut down the whole field. Wilson and his team put their heads down and spent the next decade searching for safer gene therapies. Today, his lab’s $70 million annual budget and bevy of biotech partnerships are fueling the gene therapy explosion.

The resurgence was never a sure thing.
Here’s how it happened.

Cover image:The polarizing pioneer guides a gene therapy renaissance

Credit: Matthew Bender

Full Article
Volume 97 | Issue 36

All Issues

Quote of the Week

“I have nightmares all the time. I am afraid, seriously, that the field is moving too fast.”

Guangping Gao, director, University of Massachusetts Horae Gene Therapy Center

ADVERTISEMENT
image name
Spectroscopy

Chemists build the tiniest spectrometer from a single nanowire

Device could pave the way for miniature analytical instruments

ADVERTISEMENT
ADVERTISEMENT